Level Financial Advisors Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 10.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 558 shares of the company’s stock after selling 66 shares during the quarter. Level Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $99,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Family CFO Inc bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $26,000. Steward Financial Group LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $34,000. Jackson Wealth Management LLC lifted its position in Johnson & Johnson by 1.7% in the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after buying an additional 277 shares during the last quarter. Advocacy Wealth Management Services LLC lifted its position in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after buying an additional 67 shares during the last quarter. Finally, Iron Horse Wealth Management LLC lifted its position in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after purchasing an additional 61 shares during the last quarter. 68.78% of the stock is owned by institutional investors.
Shares of JNJ stock opened at $175.74 on Thursday. The stock has a market cap of $462.44 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 3.35 and a beta of 0.66. The business’s fifty day moving average is $177.66 and its 200 day moving average is $173.09. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39.
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a $1.13 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio is currently 60.92%.
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,161 shares of company stock worth $13,895,302. Insiders own 0.35% of the company’s stock.
Several analysts have weighed in on JNJ shares. Bank of America started coverage on Johnson & Johnson in a research report on Wednesday, March 2nd. They issued a “neutral” rating for the company. Morgan Stanley lowered their price objective on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Raymond James boosted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. The Goldman Sachs Group upped their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, Credit Suisse Group upped their target price on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $190.50.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.